DaCapo Brainscience

About:

DaCapo Brainscience develops disease-modifying therapies for neurodegenerative diseases, focusing on innovative treatments.

Website: https://www.dacapobrain.com

Description:

DaCapo Brainscience is a biotechnology company focused on developing the first disease-modifying therapies for neurodegenerative diseases. With a mission centered on addressing the challenges of conditions such as Parkinson's disease, DaCapo Brainscience leverages deep expertise in the field to pioneer innovative treatments. The company's approach includes targeting the accumulation of specific proteins in the brain, which are associated with the progression of neurodegenerative diseases. DaCapo Brainscience is committed to advancing research and development to offer new paths forward for patients affected by these conditions. The team consists of professionals with extensive experience in biotechnology, working towards making significant contributions to the field of neuroscience.

Total Funding Amount:

$6.66M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2020-11-01

Founders:

Jian Peng, Katrine Bosley, Lorenz Studer, Matthew Peck, Vikram Khurana

Number of Employees:

1-10

Last Funding Date:

2022-10-12

IPO Status:

Private

Industries:

© 2025 bioDAO.ai